Skip to main content
. Author manuscript; available in PMC: 2008 Oct 6.
Published in final edited form as: Arch Toxicol. 2005 Jun 29;79(11):683–688. doi: 10.1007/s00204-005-0676-2

Table 3.

The effect of brevenal of human lymphocytes exposed to brevetoxins

Treatment N Tail moment
Mean±SE
Negative control 30 29.2+0.9
H2O2 (2.75%) 30 72.1+1.5*
Brevenal 1.0 μg/ml 9 30.8+2.6
Brevenal 100 μg/ml 3 36.3+1.7
Brevenal 1.0 μg/ml 1 h before PbTx-2 10−8 M (Sigma) 3 31.3+2.1
PbTx-2 10−8 M (Sigma) 1 h before Brevenal 1.0 μg/ml 3 33.5+0.3
Brevenal 1.0 μg/ml 1 h before PbTx-2 10−8 M (UNCW) 3 33.9+1.4
PbTx-2 10−8 M (UNCW) 1 h before Brevenal 1.0 μg/ml 3 40.3+1.9
Brevenal 1.0 μg/ml 1 h before PbTx-9 10−8 M (Sigma) 3 35.5+2.9
PbTx-9 10−8 M Sigma 1 h before Brevenal 1.0 μg/ml 3 40.1+2.4
Brevenal 1.0 μg/ml 1 h before PbTx-3 10−8 M (UNCW) 6 34.9+1.25
PbTx-3 10−8 M (UNCW) 1 h before Brevenal 1.0 μg/ml 3 42.4+0.75**
Brevenal 1.0 μg/ml simultaneously with PbTx-2 10−8 M (Sigma) 3 27.4+1.2
Brevenal 1.0 μg/ml simultaneously with PbTx-2 10−8 M (UNCW) 3 49.2+7.1
*

Significantly different from the negative control, p<0.05.

**

Significantly different from brevenal 1.0 μg/ml, p<0.05.